Rachel E Piddock
Overview
Explore the profile of Rachel E Piddock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
605
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marlein C, Piddock R, Mistry J, Zaitseva L, Hellmich C, Horton R, et al.
Cancer Res
. 2019 Jan;
79(9):2285-2297.
PMID: 30622116
Metabolic adjustments are necessary for the initiation, proliferation, and spread of cancer cells. Although mitochondria have been shown to move to cancer cells from their microenvironment, the metabolic consequences of...
2.
Abdul-Aziz A, Sun Y, Hellmich C, Marlein C, Mistry J, Forde E, et al.
Blood
. 2018 Nov;
133(5):446-456.
PMID: 30401703
Acute myeloid leukemia (AML) is an age-related disease that is highly dependent on the bone marrow (BM) microenvironment. With increasing age, tissues accumulate senescent cells, characterized by an irreversible arrest...
3.
Marlein C, Zaitseva L, Piddock R, Raso-Barnett L, Scott M, Ingham C, et al.
Leukemia
. 2018 Jul;
32(9):2073-2077.
PMID: 30030506
No abstract available.
4.
Piddock R, Marlein C, Abdul-Aziz A, Shafat M, Auger M, Bowles K, et al.
J Hematol Oncol
. 2018 May;
11(1):66.
PMID: 29769142
Conclusions: Our presented findings show that MM-derived MIF causes BMSC secretion of IL-6 and IL-8 via BMSC cMYC. Furthermore, we show that the cMYC inhibitor JQ1 can reduce BMSC secreted...
5.
Abdul-Aziz A, Shafat M, Sun Y, Marlein C, Piddock R, Robinson S, et al.
Oncogene
. 2018 Mar;
37(20):2676-2686.
PMID: 29487418
Approximately 80% of patients diagnosed with acute myeloid leukemia (AML) die as a consequence of failure to eradicate the tumor from the bone marrow microenvironment. We have recently shown that...
6.
Marlein C, Zaitseva L, Piddock R, Robinson S, Edwards D, Shafat M, et al.
Blood
. 2017 Jul;
130(14):1649-1660.
PMID: 28733324
Improvements in the understanding of the metabolic cross-talk between cancer and its microenvironment are expected to lead to novel therapeutic approaches. Acute myeloid leukemia (AML) cells have increased mitochondria compared...
7.
Piddock R, Bowles K, Rushworth S
Cancers (Basel)
. 2017 Mar;
9(4).
PMID: 28350342
Despite the development of novel treatments in the past 15 years, many blood cancers still remain ultimately fatal and difficult to treat, particularly acute myeloid leukaemia (AML) and multiple myeloma...
8.
Shafat M, Oellerich T, Mohr S, Robinson S, Edwards D, Marlein C, et al.
Blood
. 2017 Jan;
129(10):1320-1332.
PMID: 28049638
Despite currently available therapies, most patients diagnosed with acute myeloid leukemia (AML) die of their disease. Tumor-host interactions are critical for the survival and proliferation of cancer cells; accordingly, we...
9.
Pillinger G, Loughran N, Piddock R, Shafat M, Zaitseva L, Abdul-Aziz A, et al.
Oncotarget
. 2016 May;
7(26):39784-39795.
PMID: 27174919
Phosphoinositide-3-kinase (PI3K) is an enzyme group, known to regulate key survival pathways in acute myeloid leukaemia (AML). It generates phosphatidylinositol-3,4,5-triphosphate, which provides a membrane docking site for protein kinaseB activation....